|
|
|
|
|
By Ray Dogum, chief editor, Drug Discovery Online | ARMR Sciences Inc. has developed a vaccine designed with a novel adjuvant, dmLT, to neutralize fentanyl in the bloodstream before it reaches the central nervous system and binds to μ-opioid receptors (MORs). | |
|
|
|
Progressing Precision Medicine Discovery With AI | A conversation with Iya Khalil, Ph.D., Merck & Co. | We caught up with Iya Khalil, Ph.D., vice president and head of data, AI, and genome sciences at Merck & Co. to discuss Merck's creation of a foundation model that will help progress precision medicine. |
|
|
|
|
| NIH:OVCAR-3 Human Ovarian Cancer Model | Article | By Gunisha Arora, Ph.D., Labcorp Drug Discovery Solutions | Review studies using the NIH:OVCAR-3 model of human ovarian cancer in the subcutaneous setting in NSG mice with multiple standard agents and vehicles. This model has shown reproducible growth. |
|
|
| Using Synthesis And Route Design Technology To Approach API Complexity | Article | By Dr. Ryan Littich, Lonza and Dr. Juergen Swienty-Busch, Elsevier Information Systems | Leveraging computer-aided synthesis design technology and route scouting in the early stages of development can aid you in designing an efficient and cost-effective path to API manufacturing. |
|
|
| High‑Content Imaging Drives Hit‑To‑Lead For Protein Degraders | Poster | By Clark Driscoll, Erin Olin, Adam McCabe, et al., Curia | Explore Curia’s cost-effective high-content immunofluorescence workflow using the Revvity Opera Phenix™ system to efficiently identify small molecule protein degraders with rich, multi-dimensional data. |
|
|
|
| Spray Drying For Improved Solubility | Q&A | Lonza | Gain expert insights into how to develop a spray dried powder formulation and scale it from early feasibility studies to commercial manufacturing. |
|
|
|
| Non-Opioid Pain Therapeutics Summit | The Non-Opioid Pain Therapeutics Summit provides a dedicated platform to harness the current momentum in the pain space. Attendees will be learning from companies with approvals such as Tonix and Vertex, exploring late-stage strategies from innovators like Latigo and Algiax, and uncovering discovery breakthroughs from Nocion and Axonis. Join discovery, preclinical, translational and clinical industry-based experts driving the future of non-opioid pain therapies. |
|
|
|
|
|
